Cancer最新文献

{"title":"Patient navigation as a core component of global cancer care—A call to action from the Global Alliance for Cancer Patient Navigation","authors":"Anurag K. Agrawal MD,&nbsp;Kristie McComb MPH,&nbsp;Carla Thamm RN, PhD,&nbsp;Nirmala Bhoo-Pathy MD, PhD,&nbsp;Dylan Graetz MD, MPH,&nbsp;Bonny Morris RN, PhD, MSPH,&nbsp;Eduardo Cazap MD, PhD,&nbsp;Melissa Chin BSc, MBA, CHE,&nbsp;Jennifer Dent BSc, MBA,&nbsp;Margaret I. Fitch RN, PhD,&nbsp;Nishu Singh Goel MA,&nbsp;Maher H. Ibraheem MD,&nbsp;Kenneth M. Landgraf MS,&nbsp;Marion L'hôte MA,&nbsp;Nancy Peña OPN-CG, CHW,&nbsp;Carl Queiros BA,&nbsp;Kathleen Schmeler MD,&nbsp;Courtney E. Sullivan RN, PhD, CPNP-AC, CPHON,&nbsp;Andrielle Yost MPA,&nbsp;Raymond J. Chan RN, PhD,&nbsp;for the Global Alliance for Cancer Patient Navigation","doi":"10.1002/cncr.70520","DOIUrl":"10.1002/cncr.70520","url":null,"abstract":"<p>Patient navigation is generally defined as an individualized service that breaks down barriers to provide comprehensive and equitable cancer care. As the evidence base grows for patient navigation efficacy in diverse settings across the cancer continuum, navigation is increasingly recognized and adopted as an essential resource to aid in linking to and advocating for patient-centered services. To further patient navigation as a core component of cancer care, the American Cancer Society formed the Global Alliance for Cancer Patient Navigation to build awareness, evidence, and momentum and to coalesce around the core principles to aid sustainable implementation, keeping the voiced needs of people with lived experience at the forefront.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 16","pages":""},"PeriodicalIF":5.6,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.70520","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148710826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The past, present, and future treatment of BRAFV600-mutant metastatic colorectal cancer: A comprehensive review","authors":"Iris Dirven MD,&nbsp;Celina Ang MD,&nbsp;Cleo Bertels MD,&nbsp;Koen Kortbeek MD,&nbsp;Amy de Haar-Holleman MD, PhD,&nbsp;Marieke Vollebergh MD, PhD,&nbsp;Poulikos Poulikakos PhD,&nbsp;Bart Neyns MD, PhD","doi":"10.1002/cncr.70569","DOIUrl":"10.1002/cncr.70569","url":null,"abstract":"<p><i>BRAF</i>^V600-mutant metastatic colorectal cancer comprises a biologically distinct and clinically aggressive subset of metastatic colorectal cancer. Early attempts to apply single-agent <i>BRAF</i>^V600 inhibition failed because of rapid acquired resistance and reactivation of mitogen-activated protein kinase signaling. Over the last decade, rational combinations (BRAF inhibitors and epidermal growth factor receptor inhibitors with or without mitogen-activated protein kinase kinase inhibitors) have become the standard of care in the refractory setting and are now being evaluated upfront, whereas a wave of next-generation approaches (extracellular signal-regulated kinase and SHP2 inhibitors, receptor tyrosine kinase-targeted agents, and immunotherapy combinations) aims to prevent or overcome resistance. The objective of this comprehensive review was to summarize historic therapeutic approaches, current standards, and the mechanistic rationale and clinical development of next-generation strategies to combat resistance in <i>BRAF</i>^V600-mutant metastatic colorectal cancer.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 16","pages":""},"PeriodicalIF":5.6,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148719487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing safety and efficacy of asparaginase and blinatumomab therapy in frontline acute lymphoblastic leukemia regimens in diverse health care settings—international expert consensus","authors":"Daniel J. DeAngelo MD, PhD,&nbsp;Anna Avagyan MD,&nbsp;Jeanine Alfaro MD,&nbsp;Valentino Conter MD,&nbsp;Maria L. de Martino Lee MD,&nbsp;Łukasz Hutnik MD,&nbsp;Miriam Hwang MD, PhD,&nbsp;Hiroto Inaba MD, PhD,&nbsp;Atsushi Manabe MD, PhD,&nbsp;Jae H. Park MD,&nbsp;Rob Pieters MD, PhD,&nbsp;Carmelo Rizzari MD,&nbsp;Vaskar Saha MD, PhD,&nbsp;David T. Teachey MD,&nbsp;Inge M. van der Sluis MD, PhD,&nbsp;Scott C. Howard MD, MSc","doi":"10.1002/cncr.70559","DOIUrl":"10.1002/cncr.70559","url":null,"abstract":"<p>Frontline blinatumomab combined with chemotherapy has resulted in improved outcomes in both pediatric and adult patients with acute lymphoblastic leukemia and is considered the new cornerstone of acute lymphoblastic leukemia treatment. The role of asparaginase in this new landscape of acute lymphoblastic leukemia treatment was extensively discussed by an expert panel of hemato-oncologists to reach a consensus on the safety and efficacy of asparaginase in diverse settings with and without blinatumomab. Herein, the following consensus topics are presented: (1) optimal dosing of asparaginase and therapeutic drug monitoring; (2) prevention of asparaginase hypersensitivity reactions and inactivation; (3) integration of frontline blinatumomab, asparaginase, and antimetabolites; and (4) special issues of asparaginase formulations and adaptations for resource-limited settings.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 16","pages":""},"PeriodicalIF":5.6,"publicationDate":"2026-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.70559","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148704870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How low do you need to go? Association between various prostate-specific antigen response measures and clinical outcomes in metastatic castration-sensitive prostate cancer in the Veterans Health Administration data","authors":"Stephen J. Freedland MD,&nbsp;Wei Gao PhD,&nbsp;Maëlys Touya PharmD, MSc,&nbsp;Hongbo Yang PhD,&nbsp;David Russell MD, FACS,&nbsp;Jingyi Chen MS,&nbsp;Grace Chen MS,&nbsp;Jasmina I. Ivanova MA","doi":"10.1002/cncr.70494","DOIUrl":"10.1002/cncr.70494","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Multiple phase 3 metastatic castration-sensitive prostate cancer (mCSPC) studies consistently show a prostate-specific antigen (PSA) nadir of &lt;0.2 ng/mL to be the preferred threshold for PSA response. However, in real-world practice, physicians often use other metrics such as percentage of PSA decline.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective analysis of Veterans Health Administration data (2006−2024) assessed the association between PSA response and overall survival (OS) in patients with mCSPC who initiated androgen deprivation therapy (ADT) ± other treatments, using landmark analyses with adjusted Cox regressions. PSA response metrics included ≥90% PSA decline and a PSA of &lt;0.2 ng/mL within 9 months of starting therapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 4890 patients, 44% reached a PSA of &lt;0.2 ng/mL and 74% had ≥90% PSA decline. Patients with a PSA of &lt;0.2 ng/mL within 9 months of ADT initiation had a reduced risk of death after this time point (adjusted hazard ratio [HR], 0.46; 95% confidence interval [CI], 0.40−0.54) versus patients who did not. OS improvements with a PSA of &lt;0.2 ng/mL were similar, regardless of ≥90% (adjusted HR, 0.43; 95% CI, 0.35−0.52) or &lt;90% PSA decline (adjusted HR, 0.36; 95% CI, 0.23−0.56). Achieving ≥90% PSA decline without a PSA of &lt;0.2 ng/mL was unrelated to improved OS. Patients who initiated ADT plus androgen receptor pathway inhibitors versus ADT alone were more likely to achieve a PSA of &lt;0.2 ng/mL during PSA follow-up (adjusted HR, 1.71; 95% CI, 1.55−1.88).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In a real-world mCSPC setting, achieving a PSA of &lt;0.2 ng/mL (whether or not a PSA decline of 90% was reached) within 9 months of initiating ADT ± other treatments was associated with improved OS, which supports a PSA nadir of &lt;0.2 ng/mL for optimizing mCSPC outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 16","pages":""},"PeriodicalIF":5.6,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13454775/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148700215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between bisphosphonate use and risks of recurrence and mortality among hormone receptor–positive and triple-negative breast cancer patients","authors":"Liuye Huang MHS,&nbsp;Linda S. Cook PhD,&nbsp;Mei-Tzu C. Tang PhD,&nbsp;David R. Doody MS,&nbsp;Ulrike Peters PhD,&nbsp;Wei Sun PhD,&nbsp;Jeroen R. Huyghe PhD,&nbsp;Kathleen E. Malone PhD,&nbsp;Christopher I. Li MD, PhD","doi":"10.1002/cncr.70562","DOIUrl":"10.1002/cncr.70562","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Bisphosphonates (BPs) are routinely used as an adjuvant therapy for breast cancer to reduce the risk of bone recurrences given their anti-resorptive effects on bones and antitumor characteristics. However, there remains limited evidence regarding their utility across different subtypes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this population-based cohort study, the authors assessed the effects of pre- and post-diagnostic BP use on recurrence, any second breast cancer event, all-cause mortality (ACM), and breast cancer–specific mortality (BCSM) using multivariable-adjusted Cox proportional hazards models among hormone receptor–positive (HR+) and triple-negative breast cancer (TNBC) participants.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>This study enrolled 2260 HR+ and 1436 TNBC participants. The median age and follow-up time to death was 51 and 52 years old and 168.3 and 147 months in the two subtypes, respectively. Post-diagnostic BP use for at least 1 year was protective for ACM (hazard ratio [HR], 0.67; 95% confidence interval [CI], 0.49–0.93) and BCSM (HR, 0.54; 95% CI, 0.33–0.89) compared to never users in HR+ cases. Among participants who initiated BP after diagnosis only, a lower point estimates on the clinical outcomes were observed across both subtypes, reaching statistical significance for BCSM (HR, 0.62; 95% CI, 0.39–0.98) in HR+ cases. Among TNBC cases who continued BP use post-diagnosis, increased risks of recurrence (HR, 3.43; 95% CI, 1.67–7.07) and BCSM (HR, 2.54; 95% CI, 1.24–5.19) were observed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Although this study confirmed the protective effects of post-diagnostic BP use on risks of mortality among HR+ cases, further studies are required to prove the effects of post-diagnostic BP use among TNBC participants.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 16","pages":""},"PeriodicalIF":5.6,"publicationDate":"2026-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.70562","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148682768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From screening to support: Structured bibliotherapy and community-based well-being programs as adjuncts to the Older Adults with Cancer-Depression Scale","authors":"Catherine J. Michelutti MPhil,&nbsp;Fergus N. McCormack MPhil","doi":"10.1002/cncr.70565","DOIUrl":"10.1002/cncr.70565","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 16","pages":""},"PeriodicalIF":5.6,"publicationDate":"2026-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148688330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Out-of-pocket costs are not the bottom line in financial toxicity","authors":"Brittany C. Fields MD, MPH,&nbsp;Oluwasegun Afolaranmi MBBS, PhD,&nbsp;Timothy J. D. Ohlsen MD, MS,&nbsp;Juliet S. Lumati MD, MPH","doi":"10.1002/cncr.70561","DOIUrl":"10.1002/cncr.70561","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 16","pages":""},"PeriodicalIF":5.6,"publicationDate":"2026-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148676260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiomic phenotypes in nonmuscle-invasive bladder cancer: A precision biomarker guiding therapy","authors":"Colton H. Walker MD, MSCR,&nbsp;Navid Jabalameli MD,&nbsp;Soroush Rais-Bahrami MD, MBA","doi":"10.1002/cncr.70563","DOIUrl":"10.1002/cncr.70563","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 16","pages":""},"PeriodicalIF":5.6,"publicationDate":"2026-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148676286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sexual health behaviors and contraceptive practices among Canadian childhood, adolescent, and young adult cancer survivors and controls","authors":"Ismay A. E. de Beijer PhD,&nbsp;Selina R. van den Oever PhD,&nbsp;Oluwaseyi A. Lawal PhD,&nbsp;Amanda Button BSc,&nbsp;Jenny Duong BSc,&nbsp;Heide Adham MSc,&nbsp;Jennifer Giles RN, MN, NP,&nbsp;Kathleen Reynolds MD,&nbsp;Fiona S. M. Schulte PhD","doi":"10.1002/cncr.70560","DOIUrl":"10.1002/cncr.70560","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Sexual health, central to overall well-being, remains under assessed in childhood, adolescent and young adult (CAYA) cancer survivorship. This study examined sexual health outcomes among CAYA cancer survivors using repeated assessments collected as part of routine survivorship care and compared these outcomes with population-based controls.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Survivors completed one to six assessments on sexual activity, concerns about sex life, and contraceptive and condom use. Controls included age-matched Canadian Community Health Survey respondents. Multilevel and Bayesian models quantified predictors of sexual health outcomes whereas latent class growth analysis tested for high-risk subgroups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among survivors (<i>n</i> = 305; median age, 21.9 years; 49.8% male), 47.5% were not sexually active, compared with 11.2% of controls (unweighted <i>n</i> = 108,252; <i>χ</i>² = 404.35; <i>p</i> &lt; .001; odds ratio [OR], 7.18; 95% Confidence Interval [CI], 5.73–8.99). Being in a relationship predicted sexual activity (Bayesian OR, 1806.83; 95% Credible Interval [CrI], 255.08–20,535.08). Condom use was less frequent among survivors than controls (45.6% vs. 27.2%; <i>χ</i>² = 27.48; <i>p</i> &lt; .001; OR, 1.68; 95% CI, 1.42–1.99) and negatively associated with age (OR, 0.44; 95% CI, 0.26–0.74) and relationship status (OR, 0.09; 95% CI, 0.03–0.24). Not using birth control was similar between survivors and controls (26.9% vs. 25.8%; <i>χ</i>² = 0.10; <i>p</i> = .758). Within survivors, older age (OR, 0.41; 95% CI, 0.20–0.85) and higher treatment intensity (OR, 0.02; 95% CI, 0.00–0.47) were negatively associated with birth control use.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>CAYA cancer survivors demonstrate less sexual activity and condom use than controls. Higher treatment intensity is associated with less birth control use, suggesting potential misaligned fertility perceptions. Survivorship programs should integrate structured sexual health counselling.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 16","pages":""},"PeriodicalIF":5.6,"publicationDate":"2026-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13439725/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148672884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of safe chemotherapy handling behaviors among oncology nurses in a conflict-affected setting: A cross-sectional study from Gaza","authors":"Abed El-Rahman Rizq Mohammed Diab RN, MSc,&nbsp;Yousef Ibrahim Aljeesh PhD","doi":"10.1002/cncr.70550","DOIUrl":"10.1002/cncr.70550","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Chemotherapy drugs are hazardous and require strict safety protocols to protect health care workers. In the Gaza Strip, cancer is a leading cause of death, yet there is limited research on nurses’ adherence to safe chemotherapy handling practices. This study assesses the safe chemotherapy handling behaviors of nurses at the Turkish Palestinian Friendship Hospital in Gaza.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A descriptive cross-sectional study was conducted between July and August 2023. All 110 nurses at the hospital were invited to complete a validated, self-administered questionnaire based on the Nova Scotia Health Authority Chemotherapy Checklist. Data were analyzed using SPSS v25 with descriptive statistics, <i>t</i>-tests, and analysis of variance.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The response rate was 96.36% (<i>n</i> = 106). The mean self-reported scores for safe behavior domains were: safe handling before administration (81.77%), safe handling during administration (71.33%), safe disposal of equipment (83.05%), and safe disposal of cytotoxic body fluids (72.84%). These scores reflect nurses' perceptions of their own practices rather than objectively observed compliance. Significant associations were found between safe behaviors and age (<i>p</i> = .012), years of nursing experience (<i>p</i> = .001), oncology experience (<i>p</i> = .044), qualifications (<i>p</i> = .004), and previous training (<i>p</i> = .003).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Although nurses demonstrated moderate to good compliance with chemotherapy safety protocols, critical gaps remain, particularly in drug administration and disposal practices. Regular targeted training, protocol reinforcement, and hiring of specialized oncology nurses are urgently needed.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 16","pages":""},"PeriodicalIF":5.6,"publicationDate":"2026-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148672879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}